Amgen (Thousand Oaks, CA) has appointed Fabrizio Bonanni senior vice president, quality and compliance. Mr. Bonanni most recently held the position of corporate vice president, regulatory/clinical affairs at Baxter International. He succeeds Daryl Hill, who retired in March after 15 years with Amgen.

Genelabs Technologies (Redwood City, CA) has announced the retirement of Irene Chow as president and CEO. Dr. Chow has been appointed chairman of the board of directors, and will be succeeded as president by James A.D. Smith, who was promoted from COO, a position he has held since October 1996.

ChiRex (Stamford, CT) has announced the appointment of Thomas I.H. Dubin as vice president, general counsel and secretary. Previously, Mr. Dubin was assistant general counsel, corporate affairs of Warner-Lambert, and was formerly with Cravath, Swaine & Moore in New York.

Diana D. Lees has been named director, new business ventures at CombiChem (San Diego, CA). Previously, she was market development manager at Argonaut Technologies. CombiChem has also announced the departure of Karin Eastham, CFO and vice president, finance and administration, to pursue another opportunity.

Procept (Cambridge, MA) has named Michael Fitzgerald chief financial officer and vice president of finance. He joins Procept from CytoMed, where he served as vice president and CFO.

David Foster has been named director of government relations at Biogen (Cambridge, MA). He joins Biogen from Genzyme, where he served in the same capacity, and before that served as deputy general counsel for the US Department of Health and Human Services.

EntreMed (Rockville, MD) has named Joanna C. Horobin senior vice president of commercial development, a newly created post. Dr. Horobin comes to EntreMed from Rhône-Poulenc Rorer, where she served as vice president of corporate marketing, oncology.

Embrex (Research Triangle Park, NC) has appointed Brian Hrudka vice president, global commercial development. Most recently, he led the GMP manufacturing, logistics, and customer service divisions at Novartis Animal Health.

Edward L. Jacobs has joined SuperGen (San Ramon, CA) as executive vice president, commercial operations. Before joining the company, he was employed at Sequus Pharmaceuticals as senior vice president, commercial operations.

Advanced Cell Technology (Worcester, MA) has named Robert Lanza senior director of tissue engineering and transplant medicine. Dr. Lanza joins ACT from BioHybrid Technologies, where he has spent the past nine years, most recently as director of transplantation biology.

David J. Main, vice president of corporate development for Inex Pharmaceuticals (Vancouver, BC, Canada), has been named to replace James J. Miller as president and CEO, effective in July. Dr. Miller will continue on in his position as chairman of the board.

Kevin Mullane has been appointed to the post of executive vice president, research at Axiom Biotechnologies (San Diego, CA). He joins Axiom from Chugai Biopharmaceuticals, where he was senior vice president, research and development.

Cytel (San Diego, CA) has announced the appointment of Lisabeth F. Murphy to its board of directors. Ms. Murphy is currently executive vice president, intellectual property and legal affairs at Elan.

Pharmacopeia (Princeton, NJ) has promoted Bruce Myers to senior vice president and chief financial officer, replacing Lewis J. Shuster, who becomes president and COO of the company's laboratory operations. Mr. Myers joined Pharmacopeia last year as CFO of its subsidiary, Molecular Simulations.

RiboGene (Hayward, CA) has announced the appointment of Anastassios D. Retzios as director of clinical operations. Dr. Retzios was previously ats Alpha Therapeutic, where he served most recently as associate director of clinical research.

David M. Rosen has been named vice president of operations, a newly created position, at Hyseq (Sunnyvale, CA). He joins the company from Celtrix Pharmaceuticals, where he was most recently senior vice president, R&D. Hyseq also announced two promotions: Mark Gitter to CFO, and Nandini Tandon to vice president, corporate development and corporate communications.

John J. Serbin, formerly vice president of marketing and corporate development at Point Biomedical, has been appointed to the newly created position of vice president, corporate development at Idun Pharmaceuticals (La Jolla, CA).

Joel Claiborne Stephens has been named director of population genomics at Genaissance Pharmaceuticals (New Haven, CT). Before his appointment, Dr. Stephens headed the bioinformatics group at the National Cancer Institute's laboratory of genomic diversity.

Boston Scientific Corp. (Natick, MA) has named James R. Tobin as president and chief executive officer. Mr. Tobin, who will also serve on the company's board, recently resigned from his positions as president and CEO of Biogen.

British Biotech (Oxford, UK) has announced the appointment of Tony Weir as finance director, succeeding Malcolm Fallen, who resigned from the board of directors in March. Mr. Weir joined the company in 1990, and has been finance director of its principal operating subsidiary, British Biotech Pharmaceuticals, since 1997.